Kian Chuan Sia

Dr. Kian Chuan Sia

Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Molecular Therapy
Verified
Journal Article
Open access
YYYulyana Yulyana
Yulyana Yulyana
IHIvy A. W. Ho
Ivy A. W. Ho
KSKian Chuan Sia
Kian Chuan Sia
JNJennifer P Newman
Jennifer P Newman
XTXin Yi Toh
Xin Yi Toh
PLPaula Y P Lam
Paula Y P Lam
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in the world. The multi-kinase inhibitor sorafenib only demonstrated marginal improvement in overall survival for advanced disease prompted the search for alternative treatment options. Human mesenchymal stem cells (MSCs) have the ability to home to tumor cells. However, its functional roles on the tumor microenvironment remain controversial. Herein, we showed that conditioned media derived from human fetal MSC (CM-hfMSCs) expressed high level of the insulin growth factor binding proteins IGFBPs and can sequester free IGFs to inhibit HCC cell proliferation. The inhibitory effect of IGFBPs on IGF signaling was further evident from the reduction of activated IGF-1R and PI3K/Akt, leading eventually to the induction of cell cycle arrest. We also demonstrated that CM-hfMSCs could enhance the therapeutic efficacy of sorafenib and sunitinib. To the best of our knowledge, this is the first report to show that CM-hfMSCs has a tumor-specific, anti-proliferative effect that is not observed with normal human hepatocyte cells and patient-derived matched normal tissues. Our results thus suggest that CM-hfMSCs can provide a useful tool to design alternative/adjuvant treatment strategies for HCC, especially in related function to potentiate the effects of chemotherapeutic drugs.

11 April 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DCDawn Q Chong
Dawn Q Chong
XTXin Y Toh
Xin Y Toh
IHIvy A. W. Ho
Ivy A. W. Ho
KSKian Chuan Sia
Kian Chuan Sia
JNJennifer P Newman
Jennifer P Newman
PLPaula Yp Lam
Paula Yp Lam
The treatment of glioblastoma multiforme (GBM) is an unmet clinical need. The 5-year survival rate of patients with GBM is less than 3%. Temozolomide (TMZ) remains the standard first-line treatment regimen for gliomas despite the fact that more than 90% of recurrent gliomas do not respond to TMZ after repeated exposure. We have also independently shown that many of the Asian-derived glioma cell lines and primary cells derived from Singaporean high-grade glioma patients are indeed resistant to TMZ. This issue highlights the need to develop new effective anti-cancer treatment strategies. In a recent study, wild-type epidermal growth factor receptor (wtEGFR) has been shown to phosphorylate a truncated EGFR (known as EGFRvIII), leading to the phosphorylation of STAT proteins and progression in gliomagenesis. Despite the fact that combination of EGFR targeting drugs and rapamycin has been used before, the effect of mono-treatment of Nimotuzumab, rapamycin and combination therapy in human glioma expressing different types of EGFR is not well-studied. Herein, we evaluated the efficacy of dual blockage using monoclonal antibody against EGFR (Nimotuzumab) and an mTOR inhibitor (rapamycin) in Caucasian patient-derived human glioma cell lines, Asian patient-derived human glioma cell lines, primary glioma cells derived from the Mayo GBM xenografts, and primary short-term glioma culture derived from high-grade glioma patients. The combination effect of Nimotuzumab and rapamycin was examined in a series of primary human glioma cell lines and glioma cell lines. The cell viability was compared to TMZ treatment alone. Endogenous expressions of EGFR in various GBM cells were determined by western blotting. The results showed that combination of Nimotuzumab with rapamycin significantly enhanced the therapeutic efficacy of human glioma cells compared to single treatment. More importantly, many of the Asian patient-derived glioma cell lines and primary cells derived from Singaporean high-grade gliomas, which showed resistance to TMZ, were susceptible to the combined treatments. In conclusion, our results strongly suggest that combination usage of Nimotuzumab and rapamycin exert higher cytotoxic activities than TMZ. Our data suggest that this combination may provide an alternative treatment for TMZ-resistant gliomas regardless of the EGFR status.

30 June 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
IHIvy A. W. Ho
Ivy A. W. Ho
YYYulyana Yulyana
Yulyana Yulyana
KSKian Chuan Sia
Kian Chuan Sia
JNJennifer P. Newman
Jennifer P. Newman
CGChang M. Guo
Chang M. Guo
PLPaula Y. P. Lam
Paula Y. P. Lam
Human bone marrow‐derived mesenchymal stem cells (MSCs) have the unique ability to home toward injuries or tumor sites. We have previously shown that the tumor‐tropic property is dependent on the intrinsic expression and activity of the matrix remodeling gene, matrix metalloproteinase 1 (MMP‐1). Herein, crosstalk between MMP‐1/protease activated receptor 1 (PAR‐1) and the G‐protein coupled receptor stromal‐derived growth factor 1 (SDF‐1)/C‐X‐C chemokine receptor 4 (CXCR‐4) in facilitating cell migration was investigated. Gain‐of‐function and RNA interference (RNAi) technology were used to evaluate the interplay between the key players. The downstream effect on the tumor‐tropic migration of MSCs was investigated using modified Boyden chamber assay. Neutralizing PAR‐1 activation using monoclonal antibody and targeted knockdown of MMP‐1 using RNAi resulted in decreased expression of SDF‐1, which was not observed in control‐RNAi‐transfected cells. Over‐expression of CXCR‐4 failed to promote MSC migration; the percentage of migrated cells toward tumor cell conditioned medium was similar to the vector‐transduced and the CXCR‐4‐transduced MSCs. Furthermore, inhibition of SDF‐1/CXCR‐4 signaling using AMD3100 reduced MSC migration through the deregulation of MMP‐1 promoter activities, protein expression, and metalloproteinase activity. Collectively, our results showed that MMP‐1‐mediated MSC tumor tropism is dependent on crosstalk with the SDF‐1/CXCR‐4 axis.—Ho, I. A. W., Yulyana, Y., Sia, K. C., Newman, J. P., Guo, C. M., Hui, K. M., Lam, P. Y. P., Matrix metalloproteinase‐1‐mediated mesenchymal stem cell tumor tropism is dependent on crosstalk with stromal derived growth factor 1/C‐X‐C chemokine receptor 4 axis. FASEB J. 28, 4359–4368 (2014). www.fasebj.org

10 October 2015 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
YYYulyana Yulyana
Yulyana Yulyana
ATArtak Tovmasyan
Artak Tovmasyan
IHIvy A. W. Ho
Ivy A. W. Ho
KSKian Chuan Sia
Kian Chuan Sia
JNJennifer P Newman
Jennifer P Newman
PLPaula Yp Lam
Paula Yp Lam

13 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
KSKian Chuan Sia
Kian Chuan Sia
ZFZhen Ying Fu
Zhen Ying Fu
RCRoy Y. Calne
Roy Y. Calne
ANAmit C. Nathwani
Amit C. Nathwani
KLKok Onn Lee
Kok Onn Lee
SGShu Uin Gan
Shu Uin Gan
We have previously used a hepatotropic adeno-associated viral (AAV) vector with a modified human insulin gene to treat diabetic mice. The HLP (hybrid liver-specific promoter) used was constitutively active and non-responsive to glucose. In this study, we examined the effects of addition of glucose responsive elements (R3G) and incorporation of a 3′ albumin enhancer (3′iALB) on insulin expression. In comparison with the original promoter, glucose responsiveness was only observed in the modified promoters in vitro with a 36 h lag time before the peak expression. A 50% decrease in the number of viral particles at 5 × 109 vector genome (vg)/mouse was required by AAV8-R3GHLP-hINSco to reduce the blood sugar level to near normoglycemia when compared to the original AAV8-HLP-hINSco that needed 1 × 1010 vg/mouse. The further inclusion of an 860 base-pairs 3′iALB enhancer component in the 3′ untranslated region increased the in vitro gene expression significantly but this increase was not observed when the packaged virus was systemically injected in vivo. The addition of R3G to the HLP promoter in the AAV8-human insulin vector increased the insulin expression and secretion, thereby lowering the required dosage for basal insulin treatment. This in turn reduces the risk of liver toxicity and cost of vector production.

1 June 2007 in Molecular Therapy
Verified
Journal Article
Open access
PLPaula Yp Lam
Paula Yp Lam
KSKian Chuan Sia
Kian Chuan Sia
JKJenn H Khong
Jenn H Khong
BGBart De Geest
Bart De Geest
KLKar S Lim
Kar S Lim
KHKam Man Hui
Kam Man Hui
Our previous studies have shown that transgene expression could be targeted to proliferating cells when cell cycle transcriptional regulatory elements were incorporated into herpes simplex virus type 1 (HSV-1) amplicon backbone vectors. In the study reported here, we further demonstrated the transcriptional activation of transgene expression in association with the onset of cellular proliferation using the mouse partial hepatectomy model. Moreover, transcriptional regulation could be rendered specific to human hepatocellular carcinoma (HCC) cells by inserting the chimeric gene Gal4/NF-YA under the regulation of the HCC-specific hybrid promoter. The hybrid promoter, which consists of four copies of the apolipoprotein E (ApoE) enhancer element inserted upstream of the human α1-antitrypsin(hAAT) promoter, induced an higher level of transcription than other liver-specific promoters such as alpha-fetoprotein (AFP) and albumin (Alb) promoter. As a consequence, the enhancement of tissue-specific expression in the context of Gal4/NF-YA fusion proteins enabled the monitoring of transgene expression using a bioluminescence imaging system. Furthermore, these vectors have been shown to be non-toxic and exhibited potent infectivity for proliferating primary HCC cells and HCC cell lines. Together, these results demonstrated that the new hybrid vectors could provide options for the design of safe and efficient systemic gene therapeutic strategies for human HCC.